Back to results
US 12,702,710 B2Granted
Combination therapy of MDNA55 and a vascular endothelial growth factor a (VEGF-A)
AssigneeMedicenna Therapeutics Inc.
InventorFahar Merchant
Life of this patent
Estimating the term…
Abstract
Methods for treating a central nervous system (CNS) tumor in a subject, comprising administering to the subject MD-NA55 in combination with a vascular endothelial growth factor A (VEGF-A) inhibitor administered at a subtherapeutic level.
Claims17
A method of treating a central nervous system (CNS) tumor in a subject, comprising administering to the subject MDNA55 (SEQ ID NO:
- 1) in combination with a vascular endothelial growth factor A (VEGF-A) inhibitor administered at a subtherapeutic level,
- wherein the VEGF-A inhibitor is administered at least two weeks apart from the MDNA55;
- wherein the VEGF-A inhibitor is bevacizumab or a biosimilar of bevacizumab;
- and
- wherein the CNS tumor is an IL-4 receptor (IL-4R)-positive CNS tumor.
2 more elements
A method of inhibiting a central nervous system (CNS) tumor in a subject that is characterized by IL-4 receptor (IL-4R) expression, comprising:
- a) contacting the CNS tumor with MDNA55 (SEQ ID NO:
- 1);
- and
- b) contacting the CNS tumor with a subtherapeutic level of a vascular endothelial growth factor A (VEGF-A) inhibitor at least two weeks apart from the contact with the MDNA55,
- wherein the VEGF-A inhibitor is bevacizumab or a biosimilar of bevacizumab.
2 more elements
Dependencies are inferred from the claim text.